&w=3840&q=100)
AstraZeneca Pharma shares surge 12% after Q4 results; profit jumps 48%
Shares of AstraZeneca Pharma India rallied nearly 12 per cent on Monday after its net profit for the fourth quarter of the previous financial year (Q4 FY25) jumped 48 per cent to ₹58.25 crore year-on-year (Y-o-Y).
The pharma major's stock rose as much as 11.87 per cent during the day to ₹8,919 per share, the biggest intraday gain since March 20 this year. The stock pared gains to trade 11.2 per cent higher at ₹8,875 apiece, compared to a 0.54 per cent decline in Nifty50 as of 10:54 AM.
Shares of the company extended gains to their third day while they have fallen 21 per cent this year, compared to a 4.1 per cent advance in the benchmark Nifty50. AstraZeneca Pharma has a total market capitalisation of ₹22,195.5 crore, according to BSE data. Track LIVE Stock Market Updates Here
AstraZeneca Pharma Q4 results
The pharma major reported a 48 per cent rise in consolidated net profit for Q4 FY24 to ₹58.25 crore. Total revenue from operations stood at ₹480.48 crore, up 25.3 per cent Y-o-Y.
The company also recorded significant growth across therapeutic areas, achieving a 32 per cent increase in full-year revenue compared to the previous year.
In its oncology business, the pharma major reported revenue of ₹315.85 crore in Q4FY25, a rise of 31.62 per cent. Additionally, revenue from biopharmaceuticals (cardiovascular, renal and metabolism; respiratory and immunology; and vaccines and immune therapies) rose 1.9 per cent to ₹122.74 crore. The rare disease segment grew to Rs 2 crore in Q4FY25, up from Rs 0.17 crore in Q4FY24.
AstraZeneca Pharma management commentary
'FY2024–25 marked significant progress for AstraZeneca Pharma India Limited, driven by strong growth of 32 per cent," said Bhavana Agrawal, Chief Financial Officer and Director, AstraZeneca Pharma. "This reflects our strategic focus on science, specialists, and the strength of our innovation-led portfolio. As we scale impact across therapy areas, we remain committed to delivering sustainable value to the people, society, and the planet.'
About AstraZeneca Pharma
AstraZeneca Pharma is a British-Swedish multinational pharmaceutical and biotechnology company, formed in 1999 through the merger of Sweden's Astra AB and Britain's Zeneca Group.
The company is dedicated to developing and selling innovative medicines across various therapeutic areas, including cancer, cardiovascular diseases, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation.
The company has had a major presence in India for 45 years. AstraZeneca Pharma India oversees manufacturing, sales, and marketing operations, while the company also gained global recognition for its role in developing the Oxford–AstraZeneca Covid–19 vaccine
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
39 minutes ago
- Mint
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 4 June 2025
Breakout stocks buy or sell: Indian stock markets closed in the red on Tuesday, as both the Sensex and Nifty 50 extended their losing streak to a third straight session. By the close of trading, the BSE Sensex had dropped 636.24 points, or 0.78%, settling at 80,737.51. Meanwhile, the NSE Nifty 50 slipped 174.10 points, or 0.70%, to end at 24,542.50. Sumeet Bagadia, Executive Director at Choice Broking, believes that Indian stock market sentiment is cautious to positive as the Nifty 50 index is sustaining above 24,500. Speaking on the outlook of Indian stock market, Bagadia said, ' On breaching this support the market bias may turn weak and the key benchmark index may try to test 24,150 to 24,200 levels. On the upper side, the 50-stock index is facing hurdle at 24,800. So, one should maintain stock-specific approach and look at those stocks that are looking strong on the technical chart. Looking at breakout stocks can be a good option." Sumeet Bagadia recommends five shares to buy today — Deepak Frtlsrs and Ptrchmcls Corp, Authum Investment & Infrastructure, GE Vernova T&D India, Signatureglobal (India), and India Cements. 1] Deepak Frtlsrs and Ptrchmcls Corp: Buy at ₹ 1540.10, target ₹ 1663, stop loss ₹ 1486; 2] Authum Investment & Infrastructure: Buy at ₹ 2473.6, target ₹ 2647, stop loss ₹ 2387; 3] GE Vernova T&D India: Buy at ₹ 2340.10, target ₹ 2504, stop loss ₹ 2258; 4] Signatureglobal (India): Buy at ₹ 1258.7, target ₹ 1360, stop loss ₹ 1214; 5] India Cements: Buy at ₹ 351.7, target ₹ 380, stop loss ₹ 339. Disclaimer: The views and recommendations provided in this analysis are those of individual analysts or broking companies, not Mint. We strongly advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and individual circumstances may vary.
Mint
41 minutes ago
- Mint
Scoda Tubes IPO listing date today. GMP, analysts signal positive share debut on BSE, NSE
Scoda Tubes IPO Listing: The equity shares of stainless-steel tubes and pipes manufacturer Scoda Tubes Ltd will make their debut in the Indian stock market today after the recent conclusion of its initial public offering (IPO). Scoda Tubes IPO listing date is today, 4 June 2025. Scoda Tubes IPO was open for subscription from May 28 to May 30. The IPO allotment was fixed on June 2, and Scoda Tubes IPO listing date is June 4, Wednesday. Scoda Tubes shares will be listed on both the stock exchanges, BSE and NSE. 'Trading Members of the Exchange are hereby informed that effective from Wednesday, June 04, 2025, the equity shares of Scoda Tubes Limited shall be listed and admitted to dealings on the Exchange in the list of 'T' Group of Securities,' a notice on the BSE said. Scoda Tubes shares will be in the Trade-for-Trade segment for 10 trading days. The stock will be a part of the Special Pre-open Session (SPOS) on Wednesday, June 4, 2025, the BSE notice added, and the shares will be available for trading from 10:00 AM. Ahead of the Scoda Tubes IPO listing, investors watch out for the trends in Scoda Tubes IPO grey market premium (GMP) today to gauge the listing price. Scoda Tubes IPO GMP today and analyst signal listing at a mild premium. Scoda Tubes IPO GMP is showing a bullish trend. According to market analysts, Scoda Tubes IPO GMP today is ₹ 20 per share. This means that in the grey market, the Scoda Tubes shares are trading higher by ₹ 20 apiece than their issue price. Scoda Tubes IPO GMP today signals the estimated Scoda Tubes IPO listing price would be ₹ 160 per share, which is at a premium of 14% to the issue price of ₹ 140 per share. Analysts also predict Scoda Tubes IPO listing price to be at a premium. 'Scoda is valued at a P/E of 30.43x and a P/B of 8.76x on FY24 basis reasonably in line with industry peers, and we are expecting 10%-12% listing gains and IPO allotted investors can hold for medium to long term,' said Mahesh Ojha, AVP - Research and Business Development, Hensex Securities Pvt Ltd. Scoda Tubes Ltd. is a stainless-steel tubes and pipes manufacturer based in India having over 14 years of experience. The industry forecast indicates healthy growth for the Indian SS pipes and tubes which is projected to expand at a CAGR of 6% - 8% for the FY24-FY29E period. The bidding for Scoda Tubes IPO began on Wednesday, May 28, and ended on Friday, May 30. The IPO allotment date was June 2, and the Scoda Tubes IPO listing date is today, June 4, Wednesday. Scoda Tubes IPO price band was fixed at ₹ 140 per share. The company raised ₹ 220 crore from the IPO which was entirely a fresh issue of 1.57 crore equity shares. The public issue was subscribed 53.78 times in total. The retail investors' portion was booked 19.40 times, while the non-institutional investors (NII) category was subscribed 113.03 times. The qualified institutional buyers (QIBs) portion received 69.51 times subscription. Monarch Networth Capital Ltd is the book-running lead manager of the Scoda Tubes IPO, while MUFG Intime India (Link Intime) is the IPO registrar. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Indian Express
41 minutes ago
- Indian Express
What Trump America needs to understand: A country is not a corporation
Several years ago, Nobel-Prize-winning economist Paul Krugman wrote an insightful article, 'A Country is not a Company', in which he argued that business leaders need to understand the difference between economic policy on the national and international scale and business strategy on the organisational scale. In other words, and to put it bluntly, CEOs who do not understand economic policy are ill-suited for the role. Little did many realise, including perhaps Krugman himself, that an article written in 1996 would command such resonance almost three decades on. After all, CEOs of firms that have enjoyed unbridled monopoly power — especially after the emergence of the modern corporation around the turn of the last century — have shown more than a passing tendency to use that market power to their advantage. Examples abound from Standard Oil, Exxon Corporation, IBM, Microsoft, and, more recently, big-tech companies to name a few. Firms engaged in market-based competition play a 'zero-sum game' — one gains at the expense of the other. Disciplining errant firms has been accomplished by a combination of market creativity and intervention of anti-trust authorities, but it has been a hard task. Do nations jostle for competitive advantage on the global stage the same way that firms do locally? Krugman thinks not. International trade, significantly, is not a zero-sum game. According to him, 'If the European economy does well, it need not be at US expense; indeed, if anything a successful European economy is likely to help the US economy by providing it with larger markets and selling it goods of superior quality at lower prices.' Historically, that has been the case for all economic development, and most recently in East Asia. Global interdependence and the emergence of deeply integrated value chains are proof that trade increases the size of the global economic pie. The whole point of modern trade is not to impoverish either partner(s), it is to enrich both; or else why trade at all? Colonists engaged in coercive trade; today's trade is entirely voluntary. A popular phrase attributed to George Mallory, a British mountaineer of the 1920s, captures the core motivation behind mountaineering. Why do people climb mountains? 'Because they are there,' he is famously believed to have retorted. Monopolies exploit their power because it's there; CEOs have the clout along with the capacity to get away with it. Doing the same as a country — that is, flexing muscles on the global economic stage because you have power — is entirely different. Because modern trade is a matter of choice, no one holds a gun to and forces nations to trade. Blaming 'unfair' foreign competition, therefore, for trade deficits as Donald Trump has been relentlessly doing, is politically expedient but economically disingenuous. Are trade deficits the right measure of a country's competitiveness? Krugman ponders that competitiveness cannot simply be measured by staring at trade balances and their changes. If you do that, the implications are quite dangerous — they lead to harmful steps like trade wars to promote so-called competitiveness. Trade wars often make the situation worse. Evidence of the recent madness emanating from the US in the form of tariff impositions on countries that it runs a deficit with shows that contrary to expectations, the tariffs actually weakened the US dollar. It lost nearly 10 per cent of its value since January, with over half the decline in April. The tariffs also disrupted the bond market by triggering a sell-off in the US treasuries, spiking yields and challenging its safe-haven status. This volatility forced a temporary tariff pause, highlighting the bond market's power. Interestingly, on May 28, the US Court of International Trade struck down Trump's 'Liberation Day' tariffs, ruling that they exceeded presidential authority under the International Emergency Economic Powers Act (IEEPA) of 1977. According to the verdict, these tariffs involved significant economic and political issues, requiring explicit congressional authorisation, which was absent. Poignantly, on the same day, Elon Musk officially quit his advisory role in the US administration, concluding his tenure at the Department of Government Efficiency. Even so, looming on the US horizon are inflation, recession and policy unpredictability. The Trump administration has already appealed the decision (it has been stayed by the appellate court) and the case may progress to the US Supreme Court, by which time data on the impact on the US trade deficit will be available. Economists refer to this lag as 'the J-curve effect', reflecting a nuance where financial markets adjust almost instantaneously to shocks, while goods markets adjust with a lag. In all likelihood, with the tariff retaliations we have witnessed from China, Canada, and Mexico among others, the US trade deficit could become worse. Own goal, anyone? Besides, the Triffin thesis suggests that the US must run trade deficits to provide the necessary dollars for global liquidity. So, if the US wishes to remain the hegemon and continue to enjoy the exorbitant privilege of printing dollars and importing goods and services for a song, it will need to run deficits. In fact, since 1971 when the US dollar was brusquely decoupled from gold by President Richard Nixon (the so-called 'Nixon shock'), effectively ending the gold standard and the Bretton Woods system, the US dollar has continued to meet the bulk of the global demand for liquidity. In only two years since 1973 has the US trade balance been positive. In this half-century, the US has been a most productive nation, innovation-intensive, 'competitive' and creative, enterprising and illustrious, all achieved in the presence of growing trade deficits. Blaming trade deficits for unemployment and low wages is therefore ineffective and, in many cases, unequivocally wrong, especially when they are caused by domestic factors. The US is a services-based economy — education, insurance, healthcare, banking, real estate, information technology, among other sectors contributing almost 80 per cent of GDP. Getting manufacturing back by erecting tariff walls is a futile scheme, destined to fail. The CEO of a country running economic policy must, therefore, distinguish between politically expedient rhetoric and the harms of making policy decisions based on careless arithmetic. The existence of trade deficits (or surpluses) reflects a complex interaction of many factors, especially for a country that provides global liquidity. These need to be understood clearly. Krugman's warning and the embedded advice, therefore, must be taken seriously, above all by the country that nurtured his clarity of thought. (The writer is dean, School of Humanities and Social Sciences at Shiv Nadar University, and professor of Economics. Views are personal)
